Moreover, a recent study by Saini et al. [49] evaluated the presence of CD8+ T cell populations reactive to HERV-predicted peptides in PBMCs or BMMCs (bone marrow mononuclear cells) from 34 patients with hematological malignancies, including myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), before and after 5-aza-CR treatment. This evidence concerns the gene CD8A and chronic myelomonocytic leukemia.